LONDON (SHARECAST) - Pharmaceuticals giants AstraZeneca and Abbott have dissolved their collaboration agreement covering the development of Certriad capsules.Certriad is an investigational compound that was being jointly developed for the treatment of mixed dyslipidemia.
The co-development and licence agreement with Abbott will end on 22 January 2011, Astra said.
The decision was reached after careful review of a Complete Response Letter for the Certriad new drug application issued by the US Food and Drug Administration (FDA) on 30 March 2010.
With the resulting regulatory delay the two companies decided that the development of Certriad is no longer commercially attractive.
via sharecast.com
No comments:
Post a Comment